Synergy Pharma (SGYP) Posts Q1 Loss of 18c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St futures tick up as investors weigh earnings; PayPal jumps
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices rise 1% as hostilities worsen in the Middle East
- Dollar on back foot as softer US inflation dims Fed hike bets
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
Aegis Trims PT on Synergy (SGYP) to $26 Following Q1 Results; Updates on N-T Catalysts
May 14, 2014 10:02 AM EDTAegis Capital cuts its price target on Synergy Pharmaceuticals (Nasdaq: SGYP) from $28 down to $26 while affirming its Buy rating.
Analyst Ram Selvaraju noted that Synergy's Q1 loss of $.18 per share was narrower than his expected loss of $.23 per share, based on lower R&D and G&A spending.
Selvaraju also highlighted near-term catalysts for... More
